| Impact of 18F-fluorodeoxyglucose positron emission tomography in the staging and treatment response assessment of extra-pulmonary small-cell cancer. | |
| | |
MedLine Citation:
|
PMID: 20518871 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The aim of this study was to retrospectively evaluate the value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in extrapulmonary small-cell cancer (EPSCC). Patients with EPSCC who underwent PET for staging or response assessment between 1996 and 2007 were identified from a database. Patient records were reviewed. PET-based, and conventional staging and restaging results were compared. The binary staging classification of limited disease (LD) versus extensive disease (ED) was used. Patients with LD had tumours that could be encompassed within a tolerable radiation therapy (RT) volume. Of 33 eligible patients, 12 had staging PET scans, 11 had restaging scans and 10 had both. All known gross disease sites were FDG-avid. PET and conventional stage groupings were concordant in 21 of 22 cases. One patient was appropriately upstaged from LD to ED by PET. PET detected additional disease sites, without causing upstaging in three further patients. Restaging PET scans identified previously unrecognised persistent or progressive disease in 4 of 21 cases. In four further cases, persistent FDG uptake after treatment was either false positive (n = 2) or of uncertain (n = 2) aetiology. PPV was 100% for staging and 82% for restaging. In 8 of 43 imaging episodes (19%), PET appropriately influenced management in five cases by changing treatment intent from radical to palliative, and in three cases by altering the RT volume. PET has incremental value compared to conventional imaging for staging EPSCC, and may also be useful for restaging after therapy. PET influenced patient management in 19% of 43 imaging episodes. |
| | |
Authors:
|
D L Gregory; S M Brennan; A Stillie; A Herschtal; R J Hicks; M P MacManus; D L Ball |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of medical imaging and radiation oncology Volume: 54 ISSN: 1754-9485 ISO Abbreviation: J Med Imaging Radiat Oncol Publication Date: 2010 Apr |
Date Detail:
|
Created Date: 2010-06-03 Completed Date: 2010-10-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101469340 Medline TA: J Med Imaging Radiat Oncol Country: Australia |
Other Details:
|
Languages: eng Pagination: 100-7 Citation Subset: IM |
Affiliation:
|
Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. debbiegregory@doctors.org.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Carcinoma, Small Cell
/
radionuclide imaging*,
therapy* Female Fluorodeoxyglucose F18 / diagnostic use* Humans Lung Neoplasms / radionuclide imaging, therapy Male Middle Aged Neoplasm Staging Positron-Emission Tomography / methods* Prognosis Radiopharmaceuticals / diagnostic use Reproducibility of Results Sensitivity and Specificity Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Factors influencing career choices in radiology trainees in Queensland, Australia.
Next Document: Internal-external percutaneous transhepatic biliary drainage for malignant biliary obstruction: a re...